Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Sees Large Increase in Short Interest

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 438,700 shares, a growth of 4,774.4% from the July 15th total of 9,000 shares. Currently, 4.7% of the shares of the stock are sold short. Based on an average daily volume of 316,500 shares, the short-interest ratio is currently 1.4 days.

Analyst Ratings Changes

Separately, HC Wainwright decreased their target price on Sol-Gel Technologies from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, May 20th.

Sol-Gel Technologies Stock Down 1.4 %

Sol-Gel Technologies stock traded down $0.01 during midday trading on Monday, hitting $0.36. 124,073 shares of the stock were exchanged, compared to its average volume of 150,697. The stock has a market capitalization of $10.06 million, a PE ratio of -0.44 and a beta of 1.54. The company has a fifty day simple moving average of $0.74 and a two-hundred day simple moving average of $0.90. Sol-Gel Technologies has a 52 week low of $0.33 and a 52 week high of $3.24.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings results on Monday, May 20th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). Sol-Gel Technologies had a negative return on equity of 56.20% and a negative net margin of 1,329.13%. The firm had revenue of $0.47 million for the quarter, compared to the consensus estimate of $1.30 million. As a group, equities research analysts anticipate that Sol-Gel Technologies will post -0.83 EPS for the current fiscal year.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.